Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma

Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The fir...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2021-07, Vol.13 (15), p.3745
Hauptverfasser: Vellemans, Hélène, André, Marc P. E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 15
container_start_page 3745
container_title Cancers
container_volume 13
creator Vellemans, Hélène
André, Marc P. E.
description Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.
doi_str_mv 10.3390/cancers13153745
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8345175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2559433782</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</originalsourceid><addsrcrecordid>eNpdkU1LAzEQhoMoWqpnrwEvXqpJJtkkF0GKX1ARv84hm822q91NTbaV_ntTFVHnMsPMwzvvMAgdUnICoMmps53zMVGgAiQXW2jAiGSjotB8-1e9hw5SeiE5AKgs5C7aAw5CF7wYoPsHv2r8Ow41fore9q3veny36JvQJVyHiPuZx7e2s1P_OcrcebXaLK7wY5-7-DpU09emw5N1u5iF1u6jndrOkz_4zkP0fHnxNL4eTe6ubsbnk5EDrfpRLZh2BSGceFUTrnVJQEiuGCGSUw2-ckz5SlhWV9KDs44yVZW0LJ0SREgYorMv3cWybDOd3UU7N4vYtDauTbCN-TvpmpmZhpVRwAWVIgscfwvE8Lb0qTdtk5yfz23nwzIZJoTmAFKxjB79Q1_CMnb5vA2lJJOcFJk6_aJcDClFX_-YocRsPmb-fQw-ANw0iLE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2558727406</pqid></control><display><type>article</type><title>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Vellemans, Hélène ; André, Marc P. E.</creator><creatorcontrib>Vellemans, Hélène ; André, Marc P. E.</creatorcontrib><description>Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13153745</identifier><identifier>PMID: 34359646</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Bleomycin ; Cardiovascular diseases ; Chemotherapy ; Cyclophosphamide ; Dacarbazine ; Disease control ; Doxorubicin ; Etoposide ; Fertility ; Hematological diseases ; Hematology ; Hodgkin's lymphoma ; Immune checkpoint ; Lymphocytes ; Lymphocytes B ; Lymphoma ; Malignancy ; Medical prognosis ; Neutropenia ; Patients ; Positron emission tomography ; Prednisone ; Procarbazine ; Radiation therapy ; Remission ; Remission (Medicine) ; Review ; Toxicity ; Vinblastine ; Vincristine ; Women ; Young adults</subject><ispartof>Cancers, 2021-07, Vol.13 (15), p.3745</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</citedby><cites>FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345175/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345175/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Vellemans, Hélène</creatorcontrib><creatorcontrib>André, Marc P. E.</creatorcontrib><title>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</title><title>Cancers</title><description>Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.</description><subject>Bleomycin</subject><subject>Cardiovascular diseases</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide</subject><subject>Dacarbazine</subject><subject>Disease control</subject><subject>Doxorubicin</subject><subject>Etoposide</subject><subject>Fertility</subject><subject>Hematological diseases</subject><subject>Hematology</subject><subject>Hodgkin's lymphoma</subject><subject>Immune checkpoint</subject><subject>Lymphocytes</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Neutropenia</subject><subject>Patients</subject><subject>Positron emission tomography</subject><subject>Prednisone</subject><subject>Procarbazine</subject><subject>Radiation therapy</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Review</subject><subject>Toxicity</subject><subject>Vinblastine</subject><subject>Vincristine</subject><subject>Women</subject><subject>Young adults</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1LAzEQhoMoWqpnrwEvXqpJJtkkF0GKX1ARv84hm822q91NTbaV_ntTFVHnMsPMwzvvMAgdUnICoMmps53zMVGgAiQXW2jAiGSjotB8-1e9hw5SeiE5AKgs5C7aAw5CF7wYoPsHv2r8Ow41fore9q3veny36JvQJVyHiPuZx7e2s1P_OcrcebXaLK7wY5-7-DpU09emw5N1u5iF1u6jndrOkz_4zkP0fHnxNL4eTe6ubsbnk5EDrfpRLZh2BSGceFUTrnVJQEiuGCGSUw2-ckz5SlhWV9KDs44yVZW0LJ0SREgYorMv3cWybDOd3UU7N4vYtDauTbCN-TvpmpmZhpVRwAWVIgscfwvE8Lb0qTdtk5yfz23nwzIZJoTmAFKxjB79Q1_CMnb5vA2lJJOcFJk6_aJcDClFX_-YocRsPmb-fQw-ANw0iLE</recordid><startdate>20210726</startdate><enddate>20210726</enddate><creator>Vellemans, Hélène</creator><creator>André, Marc P. E.</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210726</creationdate><title>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</title><author>Vellemans, Hélène ; André, Marc P. E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-f529c60040e8f0499b03574820074193edc28ed5a2fd7e3cac128db1bbc850573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bleomycin</topic><topic>Cardiovascular diseases</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide</topic><topic>Dacarbazine</topic><topic>Disease control</topic><topic>Doxorubicin</topic><topic>Etoposide</topic><topic>Fertility</topic><topic>Hematological diseases</topic><topic>Hematology</topic><topic>Hodgkin's lymphoma</topic><topic>Immune checkpoint</topic><topic>Lymphocytes</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Neutropenia</topic><topic>Patients</topic><topic>Positron emission tomography</topic><topic>Prednisone</topic><topic>Procarbazine</topic><topic>Radiation therapy</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Review</topic><topic>Toxicity</topic><topic>Vinblastine</topic><topic>Vincristine</topic><topic>Women</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vellemans, Hélène</creatorcontrib><creatorcontrib>André, Marc P. E.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vellemans, Hélène</au><au>André, Marc P. E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma</atitle><jtitle>Cancers</jtitle><date>2021-07-26</date><risdate>2021</risdate><volume>13</volume><issue>15</issue><spage>3745</spage><pages>3745-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Hodgkin lymphoma (HL) is a lymphoid-type hematologic disease that is derived from B cells. The incidence of this lymphoid malignancy is around 2–3/100,000/year in the western world. Long-term remission rates are linked to a risk-adapted approach, which allows remission rates higher than 80%. The first-line treatment for advanced stage classical HL (cHL) widely used today is doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) chemotherapy. Randomized studies comparing these two regimens and a recently performed meta-analysis have demonstrated consistently better disease control with BEACOPPesc. However, this treatment is not the standard of care, as there is an excess of acute hematological toxicities and therapy-related myeloid neoplasms. Moreover, there is a recurrent controversy concerning the impact on overall survival with this regimen. More recently, new drugs such as brentuximab vedotin and checkpoint inhibitors have become available and have been evaluated in combination with doxorubicin, vinblastine, and dacarbazine (AVD) for the first-line treatment of patients with advanced cHL with the objective of tumor control improvement. There are still major debates with respect to first-line treatment of advanced cHL. The use of positron emission tomography-adapted strategies has allowed a reduction in the toxicity of chemotherapy regimens. Incorporation of new drugs into the treatment algorithms requires confirmation.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34359646</pmid><doi>10.3390/cancers13153745</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2021-07, Vol.13 (15), p.3745
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8345175
source MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
subjects Bleomycin
Cardiovascular diseases
Chemotherapy
Cyclophosphamide
Dacarbazine
Disease control
Doxorubicin
Etoposide
Fertility
Hematological diseases
Hematology
Hodgkin's lymphoma
Immune checkpoint
Lymphocytes
Lymphocytes B
Lymphoma
Malignancy
Medical prognosis
Neutropenia
Patients
Positron emission tomography
Prednisone
Procarbazine
Radiation therapy
Remission
Remission (Medicine)
Review
Toxicity
Vinblastine
Vincristine
Women
Young adults
title Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T00%3A34%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20Treatment%20Options%20for%20the%20Management%20of%20Advanced%20Stage%20Hodgkin%20Lymphoma&rft.jtitle=Cancers&rft.au=Vellemans,%20H%C3%A9l%C3%A8ne&rft.date=2021-07-26&rft.volume=13&rft.issue=15&rft.spage=3745&rft.pages=3745-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13153745&rft_dat=%3Cproquest_pubme%3E2559433782%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2558727406&rft_id=info:pmid/34359646&rfr_iscdi=true